On 29 July 2026, CSL Limited (ASX: CSL) told the market it would put its next generation plasma process through human trials. The technology is called Horizon 2. The point of it is simple. Get more immunoglobulin out of the same amount of plasma.
That last bit is the whole game. Plasma is the most expensive thing CSL buys. Every extra gram of medicine squeezed from the same donation drops closer to profit.
Trials are set to start in the middle of 2027. The material will come from CSL’s Broadmeadows plant in Melbourne’s north. The testing runs at the same time as the company builds out its Kankakee site in Illinois.
Same plasma bag, more medicine inside
Immunoglobulin is not something a factory can just make faster. It starts with donated human plasma, and there is only so much of it going around.
Treating one patient for a year can take plasma from hundreds of donors. For some people it runs into the thousands. So a process that pulls more finished medicine from each litre is not a small tweak. It means more patients treated from the same donor base, and a cheaper unit cost on CSL’s biggest earner.
Horizon 2 is patented and built to lift that yield. CSL first tied it to bricks and mortar in March, when it broke ground on a $1.5 billion expansion at Kankakee that is due to run by 2031.
The July announcement is the other half of that plan. Before the new process can feed the US network, it has to clear the regulators.
Why CSL is testing a factory change like a new drug
Here is the odd part. CSL already sells immunoglobulin. It has for decades. Yet changing how it is made still means proving it in people.
Regulators treat the output of a new process as a new product. Same active medicine, different method, fresh evidence required. CSL said it has already spoken with the US Food and Drug Administration and Europe’s EMA, and the trials are meant to hand those agencies the data they want.
That is why a manufacturing update read like a drug milestone on the day, and why the market reacted the way it did.
CSL share price over 12 months, showing the recovery off the June low.[ASX]
The CSL Horizon 2 clinical trials land during a brutal year
Timing matters. CSL has had one of its worst runs as a listed company.
The stock sits down around half over the past year. Back in May, interim boss Gordon Naylor used a 90-day review to cut FY26 guidance and flag about $5 billion in write-downs, most of it tied to the Vifor deal. Revenue guidance dropped to near $15.2 billion.
Naylor, a 33-year CSL hand and former finance chief, is running the place while the board hunts for a permanent chief executive. Against that backdrop, a low-cost signal that the efficiency plan is real does quiet work on sentiment. It cost CSL nothing but an announcement to remind holders there is still an upside lever turning, not just another charge to swallow.
The shares have clawed back ground since early June, part of the choppy year the ASX 200 has handed investors. A plasma yield story, even one years from paying off, fits the recovery the market has started to price, and it gives buyers something concrete to hold on the days the broader market slides.
What the plasma manufacturing update means for the wait
Nobody should expect quick money here. The dates say so.
| When | Milestone |
| March 2026 | Ground broken on $1.5 billion Kankakee, Illinois expansion |
| 29 July 2026 | CSL confirms Horizon 2 clinical trials |
| Mid-2027 | Trials begin using Broadmeadows material |
| 2031 | Kankakee expansion due to be operational |
CSL has not said how long the trials will take, or the exact date Horizon 2 wins full approval. It promised more detail once it knows. The payoff sits years out, pinned to the Kankakee build and whatever the FDA and EMA decide.
The read for now is plain. CSL is spending to make its biggest business cheaper to run, and it is telling the market the turnaround has working parts, not just slides. The real test comes with the FY26 full-year results in August, where the numbers behind the story finally get their airing.
Also Read: DroneShield Bags $23.2M European Contracts as Margins Slip
Explore more – https://colitco.com/
FAQs
Q: What is CSL’s Horizon 2 process?
A: A patented method that produces more immunoglobulin from the same amount of plasma.
Q: When do the CSL Horizon 2 clinical trials start?
A: Mid-2027, using material made at the Broadmeadows facility in Melbourne.
Q: Why does CSL need trials for a manufacturing change?
A: Regulators treat medicine from a new process as a new product that must prove safety and efficacy.
Q: Where will Horizon 2 be used?
A: It will feed CSL’s expanded Kankakee plant in Illinois, due to be operational in 2031.
Q: Did CSL shares move on the news?
A: Yes, they rose on the day. Confirm the exact figure on the ASX.
Disclaimer: This article is general information, not financial advice. It does not account for your objectives or circumstances. Do your own research and speak with a licensed financial adviser before making any investment decision. Colitco accepts no responsibility for any loss arising from reliance on this content.
